Skip to main content
Medical information Clinical review pending

Genetic Testing

Inv16 P13q22 T1616P13q22 Gene Rearrangement Quantitative MRD Monitor Test

This test monitors minimal residual disease (MRD) in cancer patients, helping doctors track treatment effectiveness and disease progression. It measures specific gene rearrangements using advanced molecular techniques.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
5 mL (3 mL minimum) whole blood or bone marrow collected in a Lavender Top (EDTA) tube.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the sample is collected correctly in the specified tube. A completed MRD Requisition form (Form 22) with historical data must accompany the sample.
Test priceKSh 15,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Inv16 P13q22 T1616P13q22 Gene Rearrangement Quantitative MRD Monitor Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Monitoring treatment response in cancer patients.
  • ✓Detecting minimal residual disease (MRD) after therapy.
  • ✓Assessing risk of relapse in certain cancers.
  • ✓Guiding further treatment decisions.
  • ✓Patients diagnosed with AML or related conditions.
02

In plain language

What this test helps you understand

This test is used to monitor minimal residual disease (MRD) in patients with certain types of cancer, particularly acute myeloid leukemia (AML), after treatment. It helps assess treatment response and detect residual cancer cells.
The Inv16 P13q22 T1616P13q22 Gene Rearrangement Quantitative MRD Monitor Test is a specialized diagnostic tool used in cancer management. It helps healthcare providers monitor minimal residual disease (MRD) – small amounts of cancer cells remaining after treatment. Detecting MRD allows doctors to assess how well treatment is working and make informed decisions about further care.

This test quantitatively measures specific gene rearrangements linked to certain cancers, particularly acute myeloid leukemia (AML). It uses Real Time PCR technology for accurate results, crucial for understanding treatment response and disease status.

This test is typically recommended for patients diagnosed with cancer who are undergoing or have recently completed treatment. It can help track the effectiveness of therapy and detect any remaining cancer cells that might indicate a need for further intervention.

Benefits of this test include monitoring treatment efficacy, guiding decisions on further treatment, and providing valuable information for personalized cancer care. Your doctor will interpret the results in the context of your specific medical situation.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the sample is collected correctly in the specified tube. A completed MRD Requisition form (Form 22) with historical data must accompany the sample.
Sample5 mL (3 mL minimum) whole blood or bone marrow collected in a Lavender Top (EDTA) tube.
MethodologyReal Time PCR (Polymerase Chain Reaction) is used to quantitatively measure the specific gene rearrangement.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific gene rearrangements. It may not detect all types of cancer or all residual disease. Results must be interpreted by a qualified healthcare professional in the context of the patient's overall clinical picture. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

MRD stands for Minimal Residual Disease. It refers to the small number of cancer cells that may remain in the body after treatment, even when scans show no signs of cancer.
Monitoring MRD helps doctors understand how effective treatment has been and can predict the risk of the cancer returning. It allows for timely adjustments to the treatment plan if needed.
A sample of whole blood or bone marrow is required. The sample must be collected in a specific Lavender Top (EDTA) tube.
Turnaround time varies. Please contact the laboratory for specific details regarding this test.
Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp